REVOLVING PROMISSORY NOTE (DSS, INC promissory note insrument WITH, or Between, affiliates)Funding Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Texas
FUNDING AGREEMENT. This Revolving Promissory Note (the “Revolving Note” or “Note”) evidences one or more advances made by Lender to Borrower pursuant to a written advance request (the “Advance Request) made by Borrower during the term of this Note. Subject to the Lender’s sole and absolute discretion, the Lender may authorize and fund, part or all, such Lender requests under the terms of this Note and the Advance Request(s).
LICENSE AGREEMENTLicense Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Texas
This LICENSE AGREEMENT (the “Agreement”), made and effective as of July 18, 2022 (the “Effective Date”), is by and between ProPhase BioPharma, Inc. (“ProPhase”), a corporation organized and existing under the laws of the State of Delaware, having its principal office at 711 Stewart Ave, Suite 200, Garden City, NY, 11530 and Global BioLife, Inc. (“Global BioLife” or “Licensor”), a corporation organized and existing under the laws of the State of Nevada, having its principal office at 1400 Broadfield Blvd., Suite 100, Houston, Texas 77084. Each of ProPhase and Licensor are referred to herein as a “Party” and collectively as the “Parties.”
STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Nevada
This STOCKHOLDERS’ AGREEMENT (this “Agreement”) is made and entered into effective as of December 11, 2020, among IMPACT BIOLIFE SCIENCE, INC., a Nevada corporation, (the “Company”) and all of the Company’s stockholders, as listed on the signature page hereto (individually, a “Stockholder” and collectively, the “Stockholders”).
LICENSING PROCEEDS DISTRIBUTION AGREEMENTLicensing Proceeds Distribution Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations
This Agreement (the “Agreement”), entered into this 15th day of February, 2022 (‘‘the “Effective Date”), by and between GRDG Sciences, LLC, a Florida company with a business address at 234 W. Central Ave., Winter Haven, Florida 33880 (hereinafter “GRDG”), and collectively, Global BioLife, Inc. (hereinafter “Global”), Impact BioLife Sciences, Inc. to include Impact Biomedical Inc. (hereinafter “Impact”), each a Nevada corporation with a business address at 701 S Carson Street, Suite 200, Carson City, Nevada 89701, collectively referred to as the “Parties” or individually as a ‘‘Party’’.
REVOLVING PROMISSORY NOTE (Document Security Systems, INC promissory note insrument WITH, or Between, affiliates)Revolving Promissory Note • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Texas
FUNDING AGREEMENT. This Revolving Promissory Note (the “Revolving Note” or “Note”) evidence one or more advances made by Lender to Borrower pursuant to a written advance request (the “Advance Request) made by Borrower during the term of this Note. Subject to the Lender’s sole and absolute discretion, the Lender may authorize and fund, part or all, such Lender requests under the terms of this Note and the Advance Request(s).
ROYALTY AGREEMENTRoyalty Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Delaware
THIS ROYALTY AGREEMENT (the “Agreement”), made and entered into as of August 15, 2018 (the “Execution Date”), is by and between Global BioLife Inc., a Nevada corporation (“GBLI”) whose address is 4800 Montgomery Lane, Ste 210, Bethesda, MD, 20814 and Chemia Corporation, a Missouri corporation (“CHEMIA”) whose address is 11558 Rock Island Ct, Maryland Heights, MO 63043.
AMENDMENT NO. 1 TO GLOBAL BIOLIFE, INC. STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Nevada
THIS AMENDMENT NO. 1 (this “Amendment”), dated as of this 22nd day of May, 2018, amending that certain stockholders’ Agreement, dated April 26, 2017 (the “Stockholders’ Agreement), is entered into by and among Global BioLife, Inc. a Nevada corporation (the “Company”) and Global BioMedical, Inc. Holista Colltech Limited, and GRDG Sciences, LLC (each a “Stockholder” and collectively, the “Stockholders”).
LICENSE AGREEMENTLicense Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations
This LICENSE AGREEMENT (the “Agreement”), made and effective as of March 17, 2022 (the “Effective Date”), is by and between ProPhase Labs, Inc. (“ProPhase”), a corporation organized and existing under the laws of the State of Delaware having its principal office at 711 Stewart Ave, Suite 200, Garden City, NY, 11530 and Global BioLife, Inc. (“Licensor”), a corporation organized and existing under the laws of the State of Nevada having its principal office at 1400 Broadfield Blvd., Suite 100, Houston, Texas 77084. Each of ProPhase and Licensor are referred to herein as a “Party” and collectively as the “Parties”.
BioMed Technology Asia Pacific Holdings Limited (as Issuer) And Impact Biomedical, Inc (as Subscriber) SUBSCRIPTION AGREEMENTSubscription Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Hong Kong
AMENDMENT NO. 2 TO GLOBAL BIOLIFE, INC. STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Nevada
THIS AMENDMENT NO. 2 (“this Amendment”) dated as of this _____ day of August 2020, amending that certain Stockholders Agreement, dated April 26, 2018 (the “Stockholders’ Agreement”) as amended on May 22, 2018 is entered into by and among Global BioLife, Inc. a Nevada corporation (the “Company”) and Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC (each a “Stockholder” and collective, the “Stockholders”).
ADDENDUM TO ROYALTY AGREEMENTAgreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Delaware
THIS ADDENDUM TO ROYALTY AGREEMENT (the “Addendum”), made and entered into as of November 27 2018 (the “Addendum Effective Date”), is by and between Global BioLife Inc., a Nevada corporation (“GBLI”) whose address is 4800 Montgomery Lane, Ste 210, Bethesda, MD, 20814 and Chemia Corporation, a Missouri corporation (“CHEMIA’’) whose address is I 1558 Rock Island Ct, Maryland Heights, MO 63043, either of which may be referred to herein individually as a “Party” and collectively as, the “Parties”.
STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • August 2nd, 2022 • Impact Biomedical Inc. • Pharmaceutical preparations • Nevada
This STOCKHOLDERS’ AGREEMENT (this “Agreement”) is made and entered into effective as of April 26, 2017, among GLOBAL BIOLIFE INC., a Nevada corporation, (the “Company”) and all of the Company’s stockholders, as listed on the signature page hereto) individually, a “Stockholder” and collectively, the “Stockholders”).
